Expert Opinion on Pharmacotherapy

The economic impact of chronic obstructive pulmonary disease
pp. 219-228(10)
Authors: Hilleman D.E.; Faulkner M.A.

Pharmacoeconomics of opioid therapy for chronic non-malignant pain
pp. 229-235(7)
Author: Marcus D.A.

Pharmacoeconomic evidence and considerations for triptan treatment of migraine
pp. 237-248(12)
Authors: Getsios D.; Caro J.J.

Pharmacoeconomics of drug therapy for atopic dermatitis
pp. 249-255(7)
Authors: Rademaker M.; Lamb S.R.

Economic aspects of medical erectile dysfunction therapies
pp. 257-263(7)
Authors: Anastasiadis A.G.; Ghafar M.A.; Shabsigh R.; Burchardt M.

Gastrointestinal side effects of NSAIDs – pharmacoeconomic implications
pp. 265-269(5)
Authors: MacDonald T.M.; Sheen C.L.

Cost-effectiveness of antibiotic prophylaxis for bacterial arthritis
pp. 271-275(5)
Authors: Krijnen P.; Schaardenburg D.v.; Kaandorp C.

Ketolides in the treatment of respiratory infections
pp. 277-297(21)
Authors: Hoban D.J.; Zhanel G.G.

The use of retinoids in the prevention and treatment of skin cancer
pp. 299-303(5)
Author: Niles R.M.

Pharmacological treatments for rhinosinusitis
pp. 305-313(9)
Authors: Hadley J.A.; Osguthorpe J.D.; Taghizadeh F.

Lopinavir/ritonavir (ABT-378/r)
pp. 315-327(13)
Authors: Qazi N.A.; Pozniak A.L.; Morlese J.F.

Lamivudine for the treatment of chronic hepatitis B
pp. 329-339(11)
Author: Sokal E.

Seretide for obstructive lung disease
pp. 341-350(10)
Author: Chapman K.R.

Clopidogrel: a CURE in acute coronary syndromes?
pp. 351-353(3)
Author: Doggrell S.A.